Medline price target raised to $55 from $46 at Stifel

Stifel raised the firm’s price target on Medline (MDLN) to $55 from $46 and keeps a Buy rating on the shares. Medline’s Q4 performance was “better-than-expected on multiple fronts” in the company’s first quarter as a public company, the analyst tells investors. Top-line outperformance was broad-based across Medline’s segments, key product categories, and geographies, adds the analyst, who notes that Medline highlighted “multiple positive factors supporting the company’s excellent near-to-longer term fundamental outlook.”